The role of checkpoint inhibitors in paraneoplastic acute exudative polymorphous vitelliform maculopathy: report of two cases
Conclusion:
The development of paraneoplastic acute exudative polymorphous vitelliform maculopathy in melanoma patients can be triggered by treatment with nivolumab. However, achieving tumor control, which may involve continuation of nivolumab, could be the key to success.
Source: Retinal Cases and Brief Reports - Category: Opthalmology Tags: Case Report Source Type: research
More News: Brain | Corticosteroid Therapy | Melanoma | Neurology | Opthalmology | Paraneoplastic Syndrome | Skin Cancer | Vitamin A